Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Amisulpride

FDA-approved product (solution, intravenous), marketed as Barhemsys.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Amisulpride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Nausea and vomiting
  • Post operative nausea and vomiting
  • Psychosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Benzamides
FDA pharmacologic class
Dopamine-2 Receptor Antagonist FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA41.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli42.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae35.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis66.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Amisulpride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Amisulpride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • SWitching to Abilify Trial (SWAT)

    NCT00304616 · start 2004-10

    Registered record
    Registry ID
    NCT00304616
    Conditions
    Schizophrenia
    Interventions
    Aripiprazole, Solian, Olanzapine, Seroquel, Risperidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2004-10
    Completion
    2007-10
    Enrolment
    500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionAripiprazole, Solian, Olanzapine, Seroquel, Risperidone
    PhasePhase 4
    Registry statusCompleted

  • Effect of Atypical Antipsychotic Drugs Olanzapine and Amisulpride on Glucose Metabolism

    NCT01160991 · start 2004-05

    Registered record
    Registry ID
    NCT01160991
    Conditions
    Schizophrenia; Diabetes; Insulin Resistance
    Interventions
    Glucose clamp technique; Amisulpride; Olanzapine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2004-05
    Completion
    2006-10
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Diabetes; Insulin Resistance
    InterventionGlucose clamp technique; Amisulpride; Olanzapine; Placebo
    PhaseNot applicable
    Registry statusCompleted

  • Tardive Dyskinesia and Cognitive Function

    NCT00926965 · start 2003-01

    Registered record
    Registry ID
    NCT00926965
    Conditions
    Tardive Dyskinesia; Neurocognitive Function
    Interventions
    amisulpride; Olanzapine; Conventional antipsychotics
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-01
    Completion
    2007-12
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTardive Dyskinesia; Neurocognitive Function
    Interventionamisulpride; Olanzapine; Conventional antipsychotics
    PhasePhase 4
    Registry statusCompleted

  • Evaluation of the Antipsychotic Efficacy of Cannabidiol in Acute Schizophrenic Psychosis

    NCT00628290 · start 2002-10

    Registered record
    Registry ID
    NCT00628290
    Conditions
    Schizophrenia
    Interventions
    Cannabidiol; Amisulpride
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2002-10
    Completion
    2008-03
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionCannabidiol; Amisulpride
    PhasePhase 2
    Registry statusCompleted

  • Early Pharmacological and Psychological Intervention for Late Prodromal States of Psychosis

    NCT00204061 · start 2001-01

    Registered record
    Registry ID
    NCT00204061
    Conditions
    Schizophrenia; Psychoses
    Interventions
    Supportive management; Amisulpride
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2001-01
    Completion
    2005-06
    Enrolment
    124

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Psychoses
    InterventionSupportive management; Amisulpride
    PhasePhase 4
    Registry statusCompleted